Development and Characterization of 3-Dimensional Cell Culture Models of Adrenocortical Carcinoma
- PMID: 39656817
- PMCID: PMC11650001
- DOI: 10.1210/endocr/bqae159
Development and Characterization of 3-Dimensional Cell Culture Models of Adrenocortical Carcinoma
Abstract
Adrenocortical carcinoma (ACC) is a rare malignancy of the adrenal cortex that is associated with a poor prognosis. Developing effective treatment options for ACC is challenging owing to the current lack of representative preclinical models. This study addressed this limitation by developing and characterizing 3-dimensional (3D) cell cultures incorporating the ACC cell lines, MUC-1, HAC15, and H295R in a type I collagen matrix. ACC tissue samples were analyzed by immunohistochemistry to determine the presence of type I collagen in the tumor microenvironment. Cell viability and proliferation were assessed using flow cytometry and confocal microscopy. mRNA expression of steroidogenic enzymes and steroid secretion was analyzed by comparing the 3D and monolayer cell culture models. All cells were successfully cultured in a type I collagen matrix, which is highly expressed in the ACC tumor microenvironment and showed optimal viability until day 7. All 3 models showed increased metabolic and proliferative activity over time. Three-dimensional cell cultures were steroidogenic and demonstrated increased resistance to the gold standard chemotherapy, mitotane, compared with monolayer. The use of these models may lead to an improved understanding of disease pathology and provide a better representative platform for testing and screening of potential therapies.
Keywords: 3D cell culture models; adrenocortical carcinoma; drug resistance; preclinical models.
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society.
Figures





Similar articles
-
Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.Oncotarget. 2016 Nov 29;7(48):79292-79304. doi: 10.18632/oncotarget.12685. Oncotarget. 2016. PMID: 27764813 Free PMC article.
-
Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.Oncotarget. 2016 Jan 19;7(3):3233-44. doi: 10.18632/oncotarget.6564. Oncotarget. 2016. PMID: 26673009 Free PMC article.
-
Drug Synergism of Proteasome Inhibitors and Mitotane by Complementary Activation of ER Stress in Adrenocortical Carcinoma Cells.Horm Cancer. 2016 Dec;7(5-6):345-355. doi: 10.1007/s12672-016-0273-2. Epub 2016 Sep 8. Horm Cancer. 2016. PMID: 27631436 Free PMC article.
-
Adrenocortical carcinoma: review of the pathologic features, production of adrenal steroids, and molecular pathogenesis.Endocrinol Metab Clin North Am. 2015 Jun;44(2):399-410. doi: 10.1016/j.ecl.2015.02.007. Endocrinol Metab Clin North Am. 2015. PMID: 26038208 Review.
-
Current and emerging therapies for adrenocortical carcinoma--review.Adv Clin Exp Med. 2015 Mar-Apr;24(2):185-93. doi: 10.17219/acem/30645. Adv Clin Exp Med. 2015. PMID: 25931348 Review.
References
-
- Fassnacht M, Dekkers OM, Else T, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1‐G46. - PubMed
-
- Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in The Netherlands since 1993. Eur J Cancer. 2013;49(11):2579‐2586. - PubMed
-
- Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;30(2):363. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous